Medtronic today announced the commercial launch in Europe of the MiniMed Go™ Smart MDI system with the Simplera™ sensor. The system, which is the first and only solution to integrate data from the InPen™ smart insulin pen and the Simplera™ sensor into a single mobile app, is designed to help people who use multiple daily injections (MDI) to better control their diabetes. The launch will be rolled out gradually across Europe starting this month.
The MiniMed Go™ Smart MDI system marks a departure from traditional and basic connected insulin pens. It provides real-time, personalized insights, actionable dose alerts, a built-in advanced dose calculator, and continuous guidance — all accessible through a smartphone app. This intelligent decision support tool aims to address daily challenges faced by those managing diabetes with MDI.
Missing insulin doses (boluses) can significantly impact glycemic control. Research shows that skipping just two doses per week may increase HbA1C by up to 0.4,1 raising the risk of both short- and long-term complications.2
Another study found that missing two basal doses or four bolus doses over 14 days was linked to more than a 5% decrease in Time in Range.3 Real-world data4 from the previous generation of the Medtronic Smart MDI system demonstrated that users who responded to more than 75% of missed dose alerts within one hour achieved Time in Range (TIR) of 67.2% compared to the mean TIR for the cohort at 55.7%, and up to 71.5% TIR when addressing high blood sugar alerts.
The MiniMed Go™ system includes new CareLink Clinic MDI reports, which make it easier for clinicians to interpret user data and support more informed patient discussions.
In Europe, the MiniMed Go™ system is a smart diabetes management solution that connects the InPen™ smart insulin pen with the Simplera™ sensor through the single MiniMed Go™ app.Medtronic
"Smart MDI has fundamentally changed how we care for patients on multiple daily injections," said Dr Martín Cuesta Hernández, Endocrinologist, Hospital Clinico San Carlos - Madrid, Spain. "We're now making evidence-based decisions instead of relying on assumptions, which has strengthened trust and improved the quality of our conversations with patients."
In Europe, the MiniMed Go™ system with Simplera™ sensor is approved for people with insulin-requiring diabetes aged 7 years and older, as well as for children aged 2 to 6 years under the supervision of an adult caregiver. Compatibility of the Instinct Go™ sensor, made by Abbott, with MiniMed Go™ in Europe is currently pending CE mark approval. Once approved, users will have the choice between a 7-day or 15-day sensor depending on what best fits their needs.
1: Randlov, J, Poulsen, JU. How Much Do Forgotten Insulin Injections Matter to Hemoglobin A1c in People with Diabetes, J Diabetes Sci Technol. 2008; 2(2):229-235.
2: American Diabetes Association Professional Practice Committee for Diabetes. Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan
3: Danne TPA, Joubert M, Hartvig NV, Kaas A, Knudsen NN, Mader JK. Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting. Diabetes Care. 2024 Jun 1;47(6):995-1003. doi: 10.2337/dc23-2176. PMID: 38569055; PMCID: PMC11116913.
4: Laurenzi A, Edd SN, Adolfsson P, et al. Insights into the effective use of the Smart MDI system: Data from the first 1852 type 1 diabetes users. Diabet Med. 2025;42(12):e70161. doi:10.1111/dme.70161.
